Schilke Tobin
- SEC CIK
- 0001678984
In the past year, 1 open-market sale filing worth $266.3K and no purchases.
Current role at each company
- CRNX Crinetics Pharmaceuticals, Inc.Chief Financial & Infra. Ofcr.as of Sep 1, 2026
- RVNC Revance Therapeutics, Inc.CFOas of Feb 6, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $266.3K
- 1 filing
- Net
- −$266.3K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Schilke Tobin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CRNX Crinetics Pharmaceuticals, Inc.
Chief Financial & Infra. Ofcr.1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Schilke TobinChief Financial Officer | SSale | −6.71K | $39.67 | −$266.3K | −7.9%78.1K after | 10b5-1 |
RVNC Revance Therapeutics, Inc.
CFO11 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2024 (view filing) | Mar 18 | 1 day | Schilke TobinCFO | SSale | −9.36K | $5.04 | −$47.2K | −4.6%192.7K after | |
| Jul 5, 2023 (view filing) | Jul 3 | 2 days | Schilke TobinCFO | SSale | −1.70K | $25.04 | −$42.6K | −2.1%79.9K after | 10b5-1 |
| Jun 5, 2023 (view filing) | Jun 1-2 | 4 days | Schilke TobinCFO | SSale | −3.20K | $30.64 | −$98.1K | −3.8%80.8K after | 2 lots10b5-1 |
| May 16, 2023 (view filing) | May 15 | 1 day | Schilke TobinCFO | SSale | −21.4K | $34.55 | −$739.4K | −20.3%84.0K after | |
| May 2, 2023 (view filing) | May 1 | 1 day | Schilke TobinCFO | SSale | −3.20K | $31.70 | −$101.5K | −4.8%63.1K after | 10b5-1 |
| Apr 4, 2023 (view filing) | Apr 3 | 1 day | Schilke TobinCFO | SSale | −3.20K | $32.15 | −$102.9K | −4.6%66.3K after | 10b5-1 |
| Mar 9, 2023 (view filing) | Mar 9 | Same day | Schilke TobinCFO | SSale | −18.5K | $31.59 | −$585.0K | −20.2%73.2K after | |
| Mar 2, 2023 (view filing) | Mar 1 | 1 day | Schilke TobinCFO | SSale | −3.20K | $33.50 | −$107.2K | −6.1%49.4K after | |
| Feb 2, 2023 (view filing) | Feb 1 | 1 day | Schilke TobinCFO | SSale | −3.20K | $34.60 | −$110.8K | −5.5%54.7K after | |
| Jan 23, 2023 (view filing) | Jan 20 | 3 days | Schilke TobinCFO | SSale | −1.00K | $31.00 | −$31.0K | −1.7%57.9K after |